This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
RIMA: Difference between revisions
>Tracer Added Category:Pharmacology |
>Graham m wiki ref formatting |
||
| Line 1: | Line 1: | ||
{{For|irreversible monoamine oxidase inhibitors (MAOIs)|MAOI}} | {{For|irreversible monoamine oxidase inhibitors (MAOIs)|MAOI}} | ||
'''Reversible inhibitors of monoamine oxidase A''' (RIMAs) are a class of drugs which selectively and reversibly inhibit the enzyme monoamine oxidase A (MAO-A). They are used clinically in the treatment of depression and dysthymia, though they have not gained widespread market share due to limited efficacy relative to other antidepressants. Because of their reversibility and selectivity, RIMAs are safer than the older [[MAOI|monoamine oxidase inhibitors]] (MAOIs).<ref> | '''Reversible inhibitors of monoamine oxidase A''' (RIMAs) are a class of drugs which selectively and reversibly inhibit the enzyme monoamine oxidase A (MAO-A). They are used clinically in the treatment of depression and dysthymia, though they have not gained widespread market share due to limited efficacy relative to other antidepressants. Because of their reversibility and selectivity, RIMAs are safer than the older [[MAOI|monoamine oxidase inhibitors]] (MAOIs).<ref>{{cite journal | vauthors=((Fowler, J. S.)), ((Logan, J.)), ((Azzaro, A. J.)), ((Fielding, R. M.)), ((Zhu, W.)), ((Poshusta, A. K.)), ((Burch, D.)), ((Brand, B.)), ((Free, J.)), ((Asgharnejad, M.)), ((Wang, G.-J.)), ((Telang, F.)), ((Hubbard, B.)), ((Jayne, M.)), ((King, P.)), ((Carter, P.)), ((Carter, S.)), ((Xu, Y.)), ((Shea, C.)), ((Muench, L.)), ((Alexoff, D.)), ((Shumay, E.)), ((Schueller, M.)), ((Warner, D.)), ((Apelskog-Torres, K.)) | journal=Neuropsychopharmacology | title=Reversible Inhibitors of Monoamine Oxidase-A (RIMAs): Robust, Reversible Inhibition of Human Brain MAO-A by CX157 | volume=35 | issue=3 | pages=623–631 | date= February 2010 | url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833271/ | issn=0893-133X | doi=10.1038/npp.2009.167}}</ref> | ||
==Interactions== | ==Interactions== | ||
| Line 22: | Line 22: | ||
* Psychoactive substances | * Psychoactive substances | ||
** [[5-IT]]<ref>{{cite journal |url=http://onlinelibrary.wiley.com/doi/10.1002/dta.1530/abstract |title=5-(2-Aminopropyl)indole (5-IT): a psychoactive substance used for recreational purposes is an inhibitor of human monoamine oxidase (MAO) |author =Tomás Herraiz |author2 =Simon D. Brandt |journal=Drug Testing and Analysis |date=July–August 2014 |volume=6 |issue=7–8 |pages=607–613 |doi=10.1002/dta.1530 |pmid=24115740}}</ref> | ** [[5-IT]]<ref>{{cite journal |url=http://onlinelibrary.wiley.com/doi/10.1002/dta.1530/abstract |title=5-(2-Aminopropyl)indole (5-IT): a psychoactive substance used for recreational purposes is an inhibitor of human monoamine oxidase (MAO) |author =Tomás Herraiz |author2 =Simon D. Brandt |journal=Drug Testing and Analysis |date=July–August 2014 |volume=6 |issue=7–8 |pages=607–613 |doi=10.1002/dta.1530 |pmid=24115740}}</ref> | ||
** [[AMT]]<ref>Studies of Monoamine Oxidase and Semicarbazide-Sensitive Amine Oxidase II. Inhibition by α-Methylated Substrate-Analogue Monoamines, α-Methyltryptamine, α-Methylbenzylamine and Two Enantiomers of α-Methylbenzylamine | | ** [[AMT]]<ref>{{cite journal | vauthors=((Arai, Y.)), ((Toyoshima, Y.)), ((Kinemuchi, H.)) | journal=The Japanese Journal of Pharmacology | title=Studies of Monoamine Oxidase and Semicarbazide-Sensitive Amine Oxidase II. Inhibition by α-Methylated Substrate-Analogue Monoamines, α-Methyltryptamine, α-Methylbenzylamine and Two Enantiomers of α-Methylbenzylamine | volume=41 | issue=2 | pages=191–197 | date= 1986 | doi=10.1254/jjp.41.191}}</ref> | ||
===Pharmaceuticals=== | ===Pharmaceuticals=== | ||